Curing the Incurable

Exogene Therapeutics, a biotechnology company that is dedicated to solving the limitations of gene therapy, has a novel platform; EXO-DEPT, an exosome-directed enzyme prodrug therapy. This technology is based on a versatile exosome (extracellular vesicle, "EV") drug delivery platform that utilizes proprietary technology to selectively deliver therapeutic cargo to target tumors or other tissues, while minimizing effects on healthy tissue. 

The EXO-DEPT technology, developed at Stanford University in the laboratory of A.C. Matin, was demonstrated by delivering functional exogenous mRNA encoded for the HER2 positive receptor breast cancer cells, thereby, converting a harmless prodrug to a highly toxic drug that arrested tumor growth in mice.